APCER Life Sciences appoints Dr Sutinder Bindra as Global Head of Medical Affairs

Continues to build its globally integrated capabilities by opening a Hong Kong office

APCER Life Sciences, a global provider of safety, medical, regulatory, and technology services headquartered in Princeton, New Jersey, reports that Sutinder Bindra has joined the company as Global Head of Medical Affairs.

Bindra, who was most recently Head of Medical and Clinical Affairs for Pfizer’s Asia-Pacific Region, will lead a fully integrated team to provide Medical Affairs services globally, including the Asia Pacific region, from APCER’s newly established office in Hong Kong.

Bindra had several years of clinical experience in internal medicine and cardiology before joining the pharmaceutical industry in 1993.

The new APCER Life Sciences Hong Kong office is located in the Bank of East Asia Harbour View Centre in Wan Chai, at the heart of the city’s Central Business District.

You may also like

Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Vetter strengthens senior management team for growth

Three new managing directors to support global sustainable development
Manufacturing

IMed Consultancy helps Toby Orthopaedics navigate UK regulations

Regulatory consultancy ensures compliance and confidence for Miami-based company
Manufacturing

Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority

The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Regulatory

Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval

The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
Subscribe now